Holding(s) in Company

Oxford Biomedica PLC 16 March 2007 TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): Oxford BioMedica PLC 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: () An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : (Yes) The Transparency Directive requires a major shareholder to make an announcement by 20 March 2007 even though it has not been required to do so because of an acquisition or disposal of voting rights or due to a change in the total voting rights in issue. 3. Full name of person(s) subject to the notification obligation (iii): UBS Investment Bank 4. Full name of shareholder(s) (if different from 3.) (iv): N/A. Note that UBS AG now reports holdings on a disaggregated basis and this announcement relates to UBS Investment Bank alone. 5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v): 12 March 2007 6. Date on which issuer notified: 13 March 2007 7. Threshold(s) that is/are crossed or reached: Below 3% 8. Notified details: A: Voting rights attached to shares Class/type of shares Situation previous to the Triggering transaction (vi) if possible using the ISIN CODE Number of shares Number of voting Rights (viii) GB0006648157 19,832,755 19,832,755 Resulting situation after the triggering transaction (vii) Class/type of Number of shares Number of voting rights % of voting shares if possible (ix) rights using the ISIN CODE Direct Direct (x) Indirect Direct Indirect (xi) GB0006648157 Non-notifiable Non-notifiable - Below 3% - B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Date Exercise/Conversion Number of voting % of voting financial (xiii) Period/Date (xiv) rights that may be rights instrument acquired if the instrument is exercised/ converted. - - - - - Total (A+B) Number of voting rights % of voting rights Non-notifiable Below 3% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): Registered Holder Holding % Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: This disclosure has been made to fulfil the below FSA requirement: The Transparency Directive states that where a major shareholder has not been required (because of an acquisition or disposal of voting rights or due to a change in the total voting rights in issue) to make an announcement to the issuer prior to 20 March 2007, then they must do so by that date in any event. 14. Contact name: Angela Huff Associate Director, UBS AG 15. Contact telephone number: 020 7568 4981 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings